Indivior's Monthly Injectable Buprenorphine Wins Panel Backing; US FDA May Limit Dosage

Advisory committee votes 18 to 1 for approval of the opioid abuse disorder treatment with restricted distribution; members advise post-market studies, registry.

vialandmultiplesyringes_1200x675

More from US FDA Performance Tracker

More from Regulatory Trackers